What does GnSOP Monitor

• AMR rates and resistant phenotypes of community-onset and hospital onset key gram-negative species including Escherichia coli, Klebsiella, Enterobacter, Pseudomonas aeruginosa and Acinetobacter blood-stream infections by jurisdiction.

• Carbapenem, fluoroquinolone, 3rd or 4th generation cephalosporin resistant phenotypes and prevalence of extended-spectrum beta-lactamase (ESBL) and plasmid mediated AmpC producers by jurisdiction.

• Infection types associated with gram-negative organisms including Enterobacterales, P. aeruginosa and Acinetobacter species.

• Outcomes (30-day all-cause mortality, length of stay post-episode) by community- versus hospital-onset, and resistance and multi-resistant phenotypes.

• Trends using data from previous GnSOPs by jurisdiction and providing analysis and commentary on the importance of trends for clinical practice and the response to AMR.

Why does it Matter

Captures data on all four of the top ranked pathogens (critical tier) on the WHO Bacterial Priority Pathogens List.

GnSOP data:

• Supports hospital stewardship decisions

• Alerts ESBL and carbapenemase-producing organisms

• Guides empirical therapy for sepsis

• Assists hospital infection control policies

• Provides national trends to AURA and to the World Health Organisation’s Global Antimicrobial Resistance and Use Surveillance System (GLASS)